Case number 1:23-cv-00101
Novo Nordisk Inc. et al v. Viatris Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 28, 2023 | 29 | NOTICE OF SERVICE of Plaintiffs' Identification of Inventors Employed by Plaintiffs and/or Represented by Counsel for Plaintiffs - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 06/28/2023) (3) |
| Jun 22, 2023 | 28 | NOTICE OF SERVICE of (1) Defendants Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 9,764,003; 10,888,605; and 11,318,191 and (2) Defendants Initial Noninfringement Contentions filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 06/22/2023) (2) |
| Jun 21, 2023 | 27 | SCHEDULING ORDER: Joinder of Parties due by 11/17/2023. Amended Pleadings due by 11/17/2023. Fact Discovery completed by 3/1/2024. Expert Discovery due by 8/9/2024. Joint Claim Construction Brief due by 11/9/2023. A Markman Hearing is set for 12/13/2023 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 11/20/2024. A Final Pretrial Conference is set for 12/11/2024 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 12/16/2024 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 6/21/2023. (nmf) (Entered: 06/21/2023) (28) |
| Jun 20, 2023 | 26 | Joint PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Cover Letter to The Honorable Colm F. Connolly)(Egan, Brian) (Entered: 06/20/2023) (Cover Letter to The Honorable Colm F. Connolly) (1) |
| Jun 20, 2023 | 26 | Joint PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Cover Letter to The Honorable Colm F. Connolly)(Egan, Brian) (Entered: 06/20/2023) (Main Document) (28) |
| Jun 8, 2023 | 25 | Official Transcript of In-Person Scheduling Conference held on June 6, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/29/2023. Redacted Transcript Deadline set for 7/10/2023. Release of Transcript Restriction set for 9/6/2023. (nmf) (Entered: 06/08/2023) (0) |
| Jun 6, 2023 | N/A | SO ORDERED, re 24 MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 6/6/2023. (kmd) (Entered: 06/06/2023) (0) |
| Jun 6, 2023 | N/A | Minute Entry for proceedings held before Judge Colm F. Connolly - In-Person Scheduling Conference held on 6/6/2023. (Court Reporter Bonnie Archer.) Counsel to submit a revised proposed scheduling order to the Court on or before June 20, 2023. (nmf) (Entered: 06/06/2023) (0) |
| Jun 5, 2023 | 24 | MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 06/05/2023) (4) |
| May 30, 2023 | N/A | Pro Hac Vice Attorney Philip S. May for Novo Nordisk A/S and Novo Nordisk Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) (Entered: 05/30/2023) (0) |
| May 30, 2023 | N/A | SO ORDERED, re 23 MOTION for Pro Hac Vice Appearance of Attorney Philip S. May, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 5/30/2023. (kmd) (Entered: 05/30/2023) (0) |
| May 30, 2023 | 23 | MOTION for Pro Hac Vice Appearance of Attorney Philip S. May - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 05/30/2023) (4) |
| May 17, 2023 | N/A | Pro Hac Vice Attorney Bryan D. Beel and Brandon M. White for Mylan Pharmaceuticals Inc. and Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 05/17/2023) (0) |
| May 16, 2023 | N/A | Pro Hac Vice Attorney Emily J. Greb for Mylan Pharmaceuticals Inc., Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) (Entered: 05/16/2023) (0) |
| May 15, 2023 | 22 | NOTICE OF SERVICE of Novo Nordisk's Preliminary Disclosure of Asserted Claims filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 05/15/2023) (3) |
| May 10, 2023 | N/A | ORAL ORDER Setting In-Person Scheduling Conference:( A Scheduling Conference is set for 6/6/2023 at 01:30 PM in Courtroom 4B before Judge Colm F. Connolly.) Ordered by Judge Colm F. Connolly on 5/10/2023. (nmf) (Entered: 05/10/2023) (0) |
| May 10, 2023 | N/A | SO ORDERED, re 21 MOTION for Pro Hac Vice Appearance of Attorney Brandon M. White, Emily J. Greb, and Bryan D. Beel, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 5/10/2023. (kmd) (Entered: 05/10/2023) (0) |
| May 9, 2023 | 21 | MOTION for Pro Hac Vice Appearance of Attorney Brandon M. White, Emily J. Greb, and Bryan D. Beel - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 05/09/2023) (6) |
| May 8, 2023 | 18 | NOTICE OF SERVICE of (1) Disclosures Under Paragraph 3 of the District of Delaware Default Standard; and (2) Initial Disclosures Pursuant to Fed. R. Civ. P. 26(A) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 05/08/2023) (3) |
| May 8, 2023 | 19 | Joint PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 05/08/2023) (30) |
| May 8, 2023 | 20 | NOTICE OF SERVICE of (1) Defendants Initial Disclosure Under Fed. R. Civ. P. 26(a)(1) and (2) Defendants Disclosures Pursuant to the Delaware Default Standard for Discovery filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 05/08/2023) (2) |
| May 4, 2023 | N/A | SO ORDERED, re 17 STIPULATION TO EXTEND TIME to Submit Proposed Scheduling Order to May 8, 2023, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Setting Deadlines: Notice of Compliance deadline set for 5/8/2023. Ordered by Judge Colm F. Connolly on 5/4/2023. (kmd) (Entered: 05/04/2023) (0) |
| May 3, 2023 | 17 | STIPULATION TO EXTEND TIME to Submit Proposed Scheduling Order to May 8, 2023 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 05/03/2023) (2) |
| Apr 24, 2023 | 16 | SO ORDERED, re 15 STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to May 3, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. ReSet Deadlines: Notice of Compliance deadline set for 5/3/2023. Signed by Judge Colm F. Connolly on 4/24/2023. (kmd) (Entered: 04/24/2023) (2) |
| Apr 21, 2023 | 15 | STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to May 3, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) (Entered: 04/21/2023) (2) |
| Apr 21, 2023 | 14 | ANSWER to 11 Answer to Complaint, Counterclaim -- Plaintiffs' Answer to Counterclaims -- by Novo Nordisk A/S, Novo Nordisk Inc..(Blumenfeld, Jack) (Entered: 04/21/2023) (16) |
| Apr 17, 2023 | N/A | SO ORDERED, re 13 STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to April 24, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. Resetting Deadlines: Notice of Compliance deadline set for 4/24/2023. Ordered by Judge Colm F. Connolly on 4/17/2023. (kmd) (Entered: 04/17/2023) (0) |
| Apr 14, 2023 | 13 | STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to April 24, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) (Entered: 04/14/2023) (2) |
| Mar 31, 2023 | 12 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Viatris Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 03/31/2023) (2) |
| Mar 31, 2023 | 11 | ANSWER to 1 Complaint, , COUNTERCLAIM against All Plaintiffs by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 03/31/2023) (30) |
| Mar 14, 2023 | 10 | ORDER, having been assigned these cases which are listed as related to earlier filed cases that are currently proceeding on an agreed upon schedule entered by the Court; IT IS ORDERED that, on or before April 17, 2023, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed.ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 4/17/2023.) Signed by Judge Colm F. Connolly on 3/14/2023. Associated Cases: 1:23-cv-00101-CFC, 1:23-cv-00179-CFC(nmf) (Entered: 03/14/2023) (2) |
| Feb 23, 2023 | N/A | Pro Hac Vice Attorney Scott Miller, Joshua Reich, Naz Erdeniz Wehrli, Daniel J. Klein, Peter Sandel, Jenny C. Wu, Josephine Young, and Nicholas P. Groombridge for Novo Nordisk A/S and Novo Nordisk Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/23/2023) (0) |
| Feb 21, 2023 | N/A | SO ORDERED, re 9 MOTION for Pro Hac Vice Appearance of Attorney Nicholas P. Groombridge, Josephine Young, Jenny C. Wu, Peter Sandel, Daniel J. Klein, Naz E. Wehrli, Joshua Reich and Scott Mille,r filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 2/21/2023. (kmd) (Entered: 02/21/2023) (0) |
| Feb 17, 2023 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas P. Groombridge, Josephine Young, Jenny C. Wu, Peter Sandel, Daniel J. Klein, Naz E. Wehrli, Joshua Reich and Scott Miller - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 02/17/2023) (10) |
| Feb 8, 2023 | 8 | WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For Mylan Pharmaceuticals Inc. waiver sent on 1/30/2023, answer due 3/31/2023; Viatris Inc. waiver sent on 1/30/2023, answer due 3/31/2023. (Egan, Brian) (Entered: 02/08/2023) (1) |
| Feb 1, 2023 | 7 | STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) (Entered: 02/01/2023) (2) |
| Feb 1, 2023 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 02/01/2023) (0) |
| Jan 27, 2023 | 1 | COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc., Viatris Inc. ( Filing fee $ 402, receipt number ADEDC-4054183.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1-5, # 2 Civil Cover Sheet) (vfm) (Entered: 01/27/2023) (Main Document) (30) |
| Jan 27, 2023 | N/A | Remark: MDL Panel Notified. (vfm) (Entered: 01/27/2023) (0) |
| Jan 27, 2023 | 6 | Summons Issued as to Mylan Pharmaceuticals Inc. on 1/27/2023; Viatris Inc. on 1/27/2023. (Attachments: # 1 Summons Issued) (vfm) (Entered: 01/27/2023) (Main Document) (2) |
| Jan 27, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk US Holdings Inc., Corporate Parent NNAS, Corporate Parent Novo Nordisk Commercial Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo Holdings A/S, Corporate Parent Novo Nordisk Foundation for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc.. (vfm) (Entered: 01/27/2023) (2) |
| Jan 27, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,343 B2 ;8,536,122 B2 ;9,764,003 B2 ;10,888,605 B2 ;11,318,191 B2. (vfm) (Entered: 01/27/2023) (1) |
| Jan 27, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/17/2022. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 6/17/2025. (vfm) (Entered: 01/27/2023) (1) |
| Jan 27, 2023 | 1 | COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc., Viatris Inc. ( Filing fee $ 402, receipt number ADEDC-4054183.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1-5, # 2 Civil Cover Sheet) (vfm) (Entered: 01/27/2023) (Exhibit 1-5) (30) |
| Jan 27, 2023 | 1 | COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc., Viatris Inc. ( Filing fee $ 402, receipt number ADEDC-4054183.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1-5, # 2 Civil Cover Sheet) (vfm) (Entered: 01/27/2023) (Civil Cover Sheet) (2) |
| Jan 27, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 01/27/2023) (3) |
| Jan 27, 2023 | 6 | Summons Issued as to Mylan Pharmaceuticals Inc. on 1/27/2023; Viatris Inc. on 1/27/2023. (Attachments: # 1 Summons Issued) (vfm) (Entered: 01/27/2023) (Summons Issued) (2) |
